Synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFκB signaling

Biomedicine and Pharmacotherapy

Volumn 64, Issue 5, 2010, Pages 327-332

  Shirode, Amit B ^a   Sylvester, Paul W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

tocotrienol; Breast cancer; Celecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA TOCOTRIENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E2; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EPITHELIUM CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHROMANS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; VITAMIN E;

EID: 77953285620     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.09.018     Document Type: Article

References (31)

1. Agrawal A., Fentiman I.S. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008, 62:444-449.
2. Antonakopoulos N., Karamanolis D.G. The role of NSAIDs in colon cancer prevention. Hepatogastroenterology 2007, 54:1694-1700.
3. Seibert K., Masferrer J.L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994, 4:17-23.
4. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
5. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645.
6. Laible B. COX-2 inhibitors and cardiovascular toxicity: a class effect?. S D J Med 2005, 58:93-94.
7. Shafiq N., Malhotra S., Pandhi P., Nada R. Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. Indian J Exp Biol 2005, 43:614-619.
8. Sylvester P.W., Shah S. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Asia Pac J Clin Nutr 2005, 14:366-373.
9. McIntyre B.S., Briski K.P., Gapor A., Sylvester P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 2000, 224:292-301.
10. McIntyre B.S., Briski K.P., Tirmenstein M.A., Fariss M.W., Gapor A., Sylvester P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 2000, 35:171-180.
11. Shah S.J., Sylvester P.W. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med (Maywood) 2005, 230:235-241.
12. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol 2000, 57:652-658.
13. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
14. Wali V.B., Sylvester P.W. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 2007, 42:1113-1123.
15. Sylvester P.W. Vitamin E and apoptosis. Vitam Horm 2007, 76:329-356.
16. Danielson K.G., Anderson L.W., Hosick H.L. Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res 1980, 40:1812-1819.
17. Shah S., Gapor A., Sylvester P.W. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 2003, 45:236-246.
18. Tallarida R.J. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001, 298:865-872.
19. Gianni L. The future of targeted therapy: combining novel agents. Oncology 2002, 63(Suppl. 1):47-56.
20. Lev-Ari S., Zinger H., Kazanov D., Yona D., Ben-Yosef R., Starr A., et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 2005, 59(Suppl. 2):S276-S280.
21. Wu S.J., Liu P.L., Ng L.T. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol Nutr Food Res 2008, 52:921-929.
22. Pang R.P., Zhou J.G., Zeng Z.R., Li X.Y., Chen W., Chen M.H., et al. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett 2007, 251:268-277.
23. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004, 101:591-596.
24. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001, 7:429-434.
25. Shiota G., Okubo M., Noumi T., Noguchi N., Oyama K., Takano Y., et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999, 46:407-412.
26. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59:987-990.
27. Uefuji K., Ichikura T., Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001, 76:26-30.
28. Davies N.M., Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Sci 2004, 7:332-336.
29. Yap S.P., Yuen K.H., Wong J.W. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J Pharm Pharmacol 2001, 53:67-71.
30. Shishodia S., Koul D., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004, 173:2011-2022.
31. Samant G.V., Sylvester P.W. Gamma-tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signaling in neoplastic mammary epithelial cells. Cell Prolif 2006, 39:563-574.